Funding Resources
Funding Overview
Funding Strategy
Funding Opportunities
Grant Mechanisms
Training & Career
Development
Contracts Management
Review Committees
Funding News |
Research
Anticonvulsant Screening
Program
Clinical Research
Counterterrorism
Epilepsy Research Web
Neural Interfaces Program
NIH Roadmap Research
Parkinson's Web
Resources for Scientists
Stem Cell Research
Translational Research
Traumatic Brain Injury
(TBI) Research
Technology Transfer
Office
NINDS is part of the
National Institutes of
Health
Investigators at the National Institute of Neurological Disorders and Stroke (NINDS) are seeking patients with mild to moderate dementia for a clinical trial of an experimental compound. This trial will be conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD.
Eligible patients must be between the ages of 40 and 90, otherwise healthy, and ambulatory, and they must be off all antidementia medications for 1 month. All treatment-related expenses will be paid by the NIH.
To refer eligible patients, physicians should send a letter of referral and case summary to Dr. Thomas Chase, Chief, Experimental Therapeutics Branch, NINDS, NIH, Building 10, Room 5C106, 10 Center Dr. MSC 1406, Bethesda, MD 20892-1406; fax: (301) 496-6609. Please call Kimberly Mosby with any questions at (301) 496-4604 or 1-800-362-3479.
This content has been adapted from the original NINDS Notes publication. For the most up-to-date funding information, please visit the Funding Opportunities section of the NINDS web site. For the most recent information on NINDS studies, please visit the NINDS Patient Recruitment web site.